Novartis AG (NVS)
97.90
+0.62
(+0.64%)
USD |
NYSE |
Apr 24, 13:25
Novartis Cash from Financing (Quarterly): -607.00M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -607.00M |
| September 30, 2023 | -832.00M |
| June 30, 2023 | -3.637B |
| March 31, 2023 | -9.202B |
| December 31, 2022 | -3.994B |
| September 30, 2022 | -4.738B |
| June 30, 2022 | -2.302B |
| March 31, 2022 | -9.528B |
| December 31, 2021 | -3.251B |
| September 30, 2021 | -1.534B |
| June 30, 2021 | -2.939B |
| March 31, 2021 | -8.54B |
| December 31, 2020 | -2.936B |
| September 30, 2020 | 1.90B |
| June 30, 2020 | -2.185B |
| March 31, 2020 | 1.013B |
| December 31, 2019 | -1.203B |
| September 30, 2019 | -2.713B |
| June 30, 2019 | -28.00M |
| March 31, 2019 | -9.683B |
| December 31, 2018 | 453.00M |
| September 30, 2018 | -1.621B |
| June 30, 2018 | -1.53B |
| March 31, 2018 | -1.546B |
| December 31, 2017 | -2.396B |
| Date | Value |
|---|---|
| September 30, 2017 | -1.937B |
| June 30, 2017 | -3.012B |
| March 31, 2017 | -388.00M |
| December 31, 2016 | -2.303B |
| September 30, 2016 | -342.00M |
| June 30, 2016 | -1.642B |
| March 31, 2016 | -1.027B |
| December 31, 2015 | -2.775B |
| September 30, 2015 | -2.196B |
| June 30, 2015 | -2.45B |
| March 31, 2015 | -1.755B |
| December 31, 2014 | -742.00M |
| September 30, 2014 | -1.08B |
| June 30, 2014 | -2.638B |
| March 31, 2014 | -3.687B |
| December 31, 2013 | -1.518B |
| September 30, 2013 | -1.392B |
| June 30, 2013 | -2.519B |
| March 31, 2013 | -3.34B |
| December 31, 2012 | -1.144B |
| September 30, 2012 | -2.117B |
| June 30, 2012 | -1.672B |
| March 31, 2012 | -1.742B |
| December 31, 2011 | -4.22B |
| September 30, 2011 | -3.76B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-9.528B
Minimum
Mar 2022
1.90B
Maximum
Sep 2020
-3.013B
Average
-2.713B
Median
Sep 2019
Cash from Financing (Quarterly) Benchmarks
| Sandoz Group AG | -- |
| Roche Holding AG | -- |
| Amgen Inc | 2.754B |
| Incyte Corp | 0.346M |
| MorphoSys AG | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.547B |
| Cash from Investing (Quarterly) | -1.76B |
| Free Cash Flow | 11.70B |
| Free Cash Flow Per Share (Quarterly) | 0.8505 |
| Free Cash Flow to Equity (Quarterly) | 770.00M |
| Free Cash Flow to Firm (Quarterly) | 1.764B |
| Free Cash Flow Yield | 5.72% |